This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase I, Dose-finding Study of BEZ235 in Adult P...
Clinical trial

A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

Read time: 1 mins
Last updated:19th Dec 2012
To establish the maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D) of BEZ235 when administered twice daily (BID) as a single agent in patients with relapsed or refractory acute leukemia. To determine the dose-limiting toxicity (DLT)
Category Value
Study start date 2012-12-19

View full details